Global reach, higher impact
J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347
Short Report
Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Citation:
Bregni M, Ciceri F, Peccatori J. Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347. Available from https://www.jcancer.org/v02p0347.htm
Bregni M, Ciceri F, Peccatori J. Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC). J Cancer 2011; 2:347-349. doi:10.7150/jca.2.347. Available from https://www.jcancer.org/v02p0347.htm
Abstract
A variety of therapeutic options are now available for advanced renal cell cancer, including antiangiogenic and anti-mTOR agents. Allogeneic hematopoietic stem cell transplantation, through its graft-versus-tumor effect, can induce clinical responses and prolonged survival in selected cytokine-refractory patients. However, the still relevant transplant-related mortality due to toxicity and graft-versus-host disease is an obstacle to its widespread use.
Keywords: Allogeneic hematopoietic stem cell transplantation, advanced renal cell cancer, graft-versus-tumor.